<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hypermetabolic response to moderate-to-severe burn injury and management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hypermetabolic response to moderate-to-severe burn injury and management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hypermetabolic response to moderate-to-severe burn injury and management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gerd G Gauglitz, MMS, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Felicia N Williams, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marc G Jeschke, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Collins, MD, PhD, FACS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 31, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Profound metabolic alterations affect patients suffering from moderate-to-severe burns. The hypermetabolic response in burn patients is characterized by hyperdynamic circulatory, physiologic, catabolic, and immune system responses. Early recognition and treatment improves clinical outcomes [<a href="#rid1">1-4</a>]. </p><p>Attenuation of the hypermetabolic response is accomplished by altering the physical, physiologic, and biochemical environment of the burn patient with early burn wound excision, grafting, optimizing nutrition, adjusting ambient temperatures, increasing lean body mass, and pharmacologic treatments. Nonpharmacologic therapies, such as providing specific nutrients and growth factors as well as activities and exercise, are also emerging as essential components of the management of burn patients [<a href="#rid5">5,6</a>].</p><p>The metabolic changes that occur following moderate-to-severe burns and the attenuation of the hypermetabolic response are reviewed here. The general care of the burn patient, including burn wound care and nutritional support, is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/16320.html" rel="external">"Overview of the management of the severely burned patient"</a> and  <a class="medical medical_review" href="/z/d/html/821.html" rel="external">"Overview of nutrition support in burn patients"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">HYPERMETABOLIC RESPONSE</span><span class="headingEndMark"> — </span>The hypermetabolic response to injury is characterized by increased blood pressure and heart rate, peripheral insulin resistance, and increased protein and lipid catabolism, which lead to increased resting energy expenditure, increased body temperature, total body protein loss, muscle wasting, and stimulated synthesis of acute-phase proteins [<a href="#rid1">1-3,5-9</a>]. These responses occur in all trauma, surgical, or critically ill patients, but the magnitude with which they occur and their duration are particularly severe and sustained for burn patients [<a href="#rid2">2,10,11</a>]. </p><p>The cause of this complex response is not well understood. A marked and sustained increase in the secretion of catecholamines, glucocorticoids, glucagon, and dopamine initiates the cascade of events leading to an acute hypermetabolic response with its ensuing catabolic state [<a href="#rid7">7,12-19</a>]. Interleukins 1 and 6, platelet-activating factor, tumor necrosis factor (TNF), endotoxin, neutrophil-adherence complexes, reactive oxygen species, nitric oxide, and coagulation and complement cascades have been implicated in regulating this response to burn injury [<a href="#rid20">20</a>]. Once these cascades are initiated, their mediators and byproducts appear to perpetuate the persistent and increased metabolic rate associated with altered glucose metabolism [<a href="#rid21">21</a>]. Perturbations in the innate immune response to the burn injury are caused by the release of damage-associated molecular patterns (DAMPs). DAMPs bind to toll-like receptors to initiate an immunosuppressive state. Collectively, burns lead to an increased risk of systemic inflammatory response syndrome, acute respiratory distress syndrome, and multiorgan dysfunction [<a href="#rid22">22-24</a>]. </p><p class="headingAnchor" id="H3380880629"><span class="h2">Time course</span></p><p class="headingAnchor" id="H2546480057"><span class="h3">Phases</span><span class="headingEndMark"> — </span>Two distinct phases of metabolic regulation are described following injury [<a href="#rid25">25</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Ebb phase – The changes associated with the "ebb phase" occur within the first 48 hours of a burn injury [<a href="#rid25">25,26</a>]. This phase is characterized by decreased cardiac output, oxygen consumption, and metabolic rate as well as impaired glucose tolerance and hyperglycemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Flow phase – The flow phase represents a gradual increase in metabolism to reach a plateau within the first five days postinjury. This phase is associated with hyperdynamic circulation and the development of insulin resistance. In response to glucose load, insulin release is twice that of controls during this time period [<a href="#rid27">27,28</a>], and plasma glucose levels are markedly elevated [<a href="#rid28">28,29</a>]. (See  <a class="medical medical_review" href="/z/d/html/1789.html" rel="external">"Insulin action"</a>.)</p><p></p><p class="headingAnchor" id="H3986564853"><span class="h3">Duration</span><span class="headingEndMark"> — </span>The hypermetabolic response (flow phase) may last for more than 12 months after the initial event and does not resolve completely after wound closure [<a href="#rid7">7,12,19,30-32</a>]. Sustained hypermetabolic alterations include persistent elevations of the stress mediators (24 hour urine cortisol levels, serum cytokines, catecholamines, and basal energy requirements). Impaired glucose metabolism and insulin sensitivity can persist for up to three years after severe burn injury [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Magnitude</span><span class="headingEndMark"> — </span>The metabolic rate increases proportionally with burn size [<a href="#rid31">31,32</a>]. A 15 to 20 percent total body surface area (TBSA) burn injury initiates a catabolic response, including impaired immunity and accentuating fluid shifts [<a href="#rid34">34</a>]. Adults with a 20 percent TBSA burn injury develop a metabolic rate between 118 to 210 percent of that predicted by Harris-Benedict equations for basal metabolic rate [<a href="#rid35">35</a>]. Patients with burns greater than 40 percent TBSA almost always experience hypermetabolism [<a href="#rid30">30</a>]. A further increase in hypermetabolism occurs in patients with burns of 50 to 60 percent TBSA, after which there is minimal further increase in hypermetabolic rate [<a href="#rid36">36</a>].</p><p>In a prospective longitudinal study in which resting energy expenditure was measured by indirect calorimetry, stable isotope study, and body composition, children with burns greater than 40 percent TBSA developed a metabolic rate of 180 percent of the basal metabolic rate (BMR) during the acute admission, which persisted at an elevated rate of 150 percent of BMR following complete wound closure and was maintained at 110 percent of BMR at one year [<a href="#rid2">2,7</a>]. (See  <a class="medical medical_review" href="/z/d/html/817.html" rel="external">"Clinical assessment and monitoring of nutrition support in adult surgical patients"</a>.)</p><p class="headingAnchor" id="H775599561"><span class="h2">Altered hemodynamics</span><span class="headingEndMark"> — </span>Depending upon the size of the burn for both children and adults, patients will initially have a low cardiac index and will be extremely vasodilated. Both populations will go into a hyperdynamic state of tachycardia with increased cardiac output. </p><p>Depending upon the comorbidities of the adults, the patient may experience atrial fibrillation or any other rhythm that they are prone to experiencing. However, compared with children, the magnitude of hemodynamic changes in adults may not be as profound due to coexisting comorbidities [<a href="#rid37">37-39</a>]. For children, heart rates can exceed 180 percent of predicted values for age-matched children, and cardiac outputs can exceed 150 percent; both can remain elevated for up to two years after injury [<a href="#rid37">37</a>]. </p><p class="headingAnchor" id="H10"><span class="h2">Altered glucose metabolism</span><span class="headingEndMark"> — </span>Under normal circumstances, a postprandial increase in blood glucose concentration stimulates the release of insulin from pancreatic beta cells. Insulin mediates peripheral glucose uptake into skeletal muscle and adipose tissue and suppresses hepatic gluconeogenesis, thereby maintaining blood glucose homeostasis. Glucose metabolism in healthy subjects and in patients with diabetes is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1789.html" rel="external">"Insulin action"</a>.) </p><p>In critical illness, metabolic alterations can significantly change energy substrate metabolism. In order to provide glucose, release of stress mediators opposes the anabolic actions of insulin. By enhancing adipose tissue lipolysis and skeletal muscle proteolysis, stress mediators (ie, counterregulatory hormones) increase gluconeogenic substrates, including glycerol, alanine, and lactate  (<a class="graphic graphic_figure graphicRef68962" href="/z/d/graphic/68962.html" rel="external">figure 1</a>), thus augmenting hepatic glucose production in burned patients [<a href="#rid40">40-43</a>].</p><p>Hyperglycemia fails to suppress hepatic glucose release during this time, and the suppressive effect of insulin on hepatic glucose release is attenuated, significantly contributing to persistent hyperglycemia [<a href="#rid33">33,44,45</a>]. Catecholamine-mediated enhancement of hepatic glycogenolysis as well as direct sympathetic stimulation of glycogen breakdown further aggravate the hyperglycemia in response to stress [<a href="#rid41">41</a>]. Catecholamines also impair glucose disposal via alterations of the insulin-signaling pathway and GLUT4 translocation in muscle and adipose tissue, resulting in peripheral insulin resistance [<a href="#rid40">40,46</a>]. </p><p>Insulin resistance in severely burned patients begins as early as three days postinjury, predominantly in the liver [<a href="#rid47">47</a>], and lasts up three years postinjury [<a href="#rid33">33</a>]. It is primarily mediated by the persistent elevation in catecholamines and cortisol levels, which lead to increased endogenous glucose production, in conjunction with the impaired insulin-mediated glucose uptake. </p><p class="headingAnchor" id="H13"><span class="h2">Altered protein and lipid metabolism</span><span class="headingEndMark"> — </span>Alterations in metabolic pathways and proinflammatory cytokines, such as tumor necrosis factor (TNF), contribute to lean-muscle protein breakdown, both during the acute and convalescent phases in response to burn injury [<a href="#rid48">48,49</a>]. (See  <a class="medical medical_review" href="/z/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects"</a>.)</p><p>In contrast to starvation, in which lipolysis and ketosis provide energy and protect muscle reserves, a moderate-to-severe burn considerably reduces the ability of the body to use lipids as an energy source. Skeletal muscle becomes the major source of substrate for glucose production, which leads to marked wasting of lean body mass (LBM) within days after burn injury [<a href="#rid2">2,50</a>] and which persists for at least nine months post-burn [<a href="#rid7">7,51</a>]. Since skeletal muscle is responsible for 70 to 80 percent of whole-body insulin-stimulated glucose uptake, decreases in muscle mass may significantly contribute to this persistent insulin resistance post-burn injury [<a href="#rid52">52</a>]. (See  <a class="medical medical_review" href="/z/d/html/1762.html" rel="external">"Insulin resistance: Definition and clinical spectrum"</a>.)</p><p>Interestingly, the observed white adipose tissue (WAT) browning after burn injury appears to be a culprit, if not the main facilitator, of cachexia [<a href="#rid53">53</a>]. The sustained catecholamine surge in burns initiates WAT browning and the cascade of events leading to the hypermetabolic response [<a href="#rid54">54,55</a>], indicating that WAT browning may be detrimental for burn patients. Despite these findings, it remains to be determined if the attenuation of WAT browning is sufficient to overcome the impaired muscle and liver metabolic processes that have already occurred in the hypermetabolic response to the injury. </p><p>A 10 to 15 percent loss in LBM is associated with a significant increase in infection rates and marked delays in wound healing [<a href="#rid56">56</a>]. The resultant muscle weakness further prolongs mechanical ventilatory utilization, inhibits sufficient cough reflexes, and delays mobilization in protein-malnourished patients, thus contributing to mortality [<a href="#rid57">57</a>]. Persistent protein catabolism may also account for growth and developmental delay frequently observed in pediatric patients with burns greater than 40 percent TBSA [<a href="#rid58">58</a>].</p><p>The profound wasting of lean body mass is further exacerbated by immobility. The classic teaching for critically ill burn patients was prolonged bed rest and immobility; however, this increases the risk for hypertrophic ossification, contractures, muscle wasting and weakness, neuropathies, pressure necrosis and pressure ulcers, deep vein thrombosis, prolonged psychological disturbances, longer lengths of stay, and increased ventilator days. Current evidence demonstrates the safety and efficacy of early mobility protocols to shift this paradigm [<a href="#rid59">59,60</a>]. (See <a class="local">'Exercise and adjunctive measures'</a> below.)</p><p class="headingAnchor" id="H14"><span class="h1">ATTENUATION OF THE HYPERMETABOLIC RESPONSE</span><span class="headingEndMark"> — </span>Therapeutic approaches focus on attenuating or blunting the hypermetabolic response and its ensuing catabolic state. A number of different strategies are used to alter the physiologic and biochemical environment. For adults and children, we recommend early burn excision and grafting, aggressive pain control using opioids acutely, insulin, and/or <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> to maintain blood glucose levels between 110 and 150. For children, we also recommend <a class="drug drug_general" data-topicid="9456" href="/z/d/drug information/9456.html" rel="external">recombinant human growth hormone</a> (rhGH) during the chronic phase of burn care.</p><p>The hypermetabolic response can be attenuated using nonpharmacologic and pharmacologic modalities. Nonpharmacologic modalities include early wound excision and closure, nutrition support, environmental support, exercise, and other adjunctive measures. Specific pharmacotherapies that can attenuate the hypermetabolic response include pain relievers, anabolic hormones, anabolic steroids, catecholamine antagonists, and <a class="drug drug_general" data-topicid="9456" href="/z/d/drug information/9456.html" rel="external">recombinant human growth hormone</a>, if needed, for children [<a href="#rid1">1</a>]. Some pharmacotherapies are more effective in the acute rather than chronic phase of the burn injury. The acute phase is defined as the period immediately following the resuscitation phase, when the patient is hemodynamically stable, capillary permeability is restored, and diuresis has begun. It generally starts 48 to 72 hours post-burn injury. The chronic or rehabilitation phase begins when wounds are healed.</p><p><a class="drug drug_general" data-topicid="10181" href="/z/d/drug information/10181.html" rel="external">Oxandrolone</a>, which is a testosterone analog with a low level of virilizing androgenic effects, improves muscle protein catabolism, reduces weight loss and growth arrest, and increases donor-site wound healing in burn patients. It was recommended for its beneficial effects attenuating the hypermetabolic response to burn injury for adults and children in both the acute and chronic phases of burn injury [<a href="#rid61">61</a>]. However, at the manufacturer's request and because of safety concerns, approval for use was removed by the United States FDA as of June 28, 2023, and the drug will no longer be manufactured [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H16"><span class="h2">Early excision and grafting</span><span class="headingEndMark"> — </span>Early excision of necrotic tissue and wound closure has been an important advancement in the treatment of patients with severe burn injuries and a mainstay of therapy [<a href="#rid2">2,7,63-66</a>]. Early burn excision and grafting is associated with a reduction in metabolic parameters [<a href="#rid30">30,67,68</a>]. Wound closure alone, however, does not eliminate the hypermetabolic response [<a href="#rid7">7</a>]. </p><p>A meta-analysis of six randomized trials showed a significant reduction in mortality with early excision and grafting in burn patients without inhalation injury (risk ratio [RR] 0.36, 95 percent CI 0.20-0.65) compared with conservative treatment of dressing changes and delayed skin grafts following eschar separation [<a href="#rid63">63</a>]. The mean length of hospital stay was significantly shorter for the early excision group (standardized mean difference [SMD] 8.89), but the requirement for blood transfusions was significantly higher (SMD 1.65). There was no difference in duration of sepsis, wound healing time, and skin graft take between the two groups.</p><p>While burn wound closure within the first five days is optimal, it is not always possible. A retrospective study of 143 burn patients showed that a delayed primary wound closure (days 6 to 12) had a similar advantage of early wound closure in reducing risk of septicemia, mortality, morbidity, hospital stay, and cost of treatment in comparison with 449 patients treated with delayed closure, a practice that allowed wounds to granulate prior to skin grafting [<a href="#rid69">69</a>]. Early excision and skin grafting is also associated with decreased severity of hypertrophic scarring, joint contractures, and stiffness and promotes faster rehabilitation [<a href="#rid70">70,71</a>]. (See  <a class="medical medical_review" href="/z/d/html/14990.html" rel="external">"Overview of surgical procedures used in the management of burn injuries"</a>.)</p><p class="headingAnchor" id="H3375791408"><span class="h2">Propranolol</span><span class="headingEndMark"> — </span>Beta blockade attenuates the hypermetabolism in pediatric burn patients and may also be beneficial in adult burn patients [<a href="#rid72">72-76</a>]. (See  <a class="medical medical_review" href="/z/d/html/7874.html" rel="external">"Beta blockers in the treatment of hyperthyroidism"</a> and  <a class="medical medical_review" href="/z/d/html/967.html" rel="external">"Major side effects of beta blockers"</a>.)</p><p>Beta blockers blunt the effects of elevated catecholamines, resulting in decreased cardiac oxygen demand and decreased resting metabolism. Stable isotope and serial body composition studies showed that administration of <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> reduces skeletal muscle wasting and increases LBM post-burn [<a href="#rid77">77</a>]. The underlying mechanism of action is unclear, but it may cause an increase in protein synthesis in response to persistent protein breakdown and reduced peripheral lipolysis [<a href="#rid78">78</a>]. Propranolol reduces fatty infiltration of the liver, which typically occurs as the result of enhanced peripheral lipolysis and altered substrate handling [<a href="#rid79">79,80</a>].</p><p>In a randomized trial of <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> versus placebo in 25 severely burned children, propranolol significantly decreased heart rate and resting energy expenditure [<a href="#rid74">74</a>]. The net muscle protein balance, which is the difference between protein synthesis and breakdown, was increased by 82 percent over baseline in the propranolol group compared with no significant change in the untreated control group. Another randomized trial that included 179 pediatric patients with more than 30 percent TBSA burn found that administration of propranolol attenuated the hypermetabolic responses for one year post-burn [<a href="#rid81">81</a>].</p><p>Beta blockers may also improve burn outcomes [<a href="#rid75">75,81-83</a>]. A small retrospective cohort study of adult burn patients found an association between preinjury treatment with beta blockers and improved wound healing and reduced burn-related mortality [<a href="#rid75">75</a>]. There was no evidence that post-burn injury treatment with beta blockers reduced the mortality rate in adult burn patients. A separate trial found that treatment with <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> in adults (10 to 20 mg three times a day) and children (4 mg/kg/24 hours) significantly reduced the rates of infection and sepsis compared with placebo (21 versus 30 percent and 7 versus 10 percent, respectively) [<a href="#rid82">82</a>].</p><p class="headingAnchor" id="H1198115568"><span class="h2">Reduce pain and anxiety</span><span class="headingEndMark"> — </span>The metabolic rate of the burn patient is adversely affected by pain, anxiety, and activity [<a href="#rid1">1</a>]. Background, procedurally related pain, and anxiety greatly increase metabolic rates.</p><p>Burn injuries cause one of the most intense and prolonged types of pain, and judicious management of pain with intravenous analgesics, appropriate sedation, and supportive psychotherapy is important to attenuate the hypermetabolic response [<a href="#rid84">84</a>]. Intravenous opioids (continuous or bolused) are most often used to relieve pain. Supportive psychotherapy is helpful in reducing patient anxiety [<a href="#rid85">85</a>]. (See  <a class="medical medical_review" href="/z/d/html/14989.html" rel="external">"Management of burn wound pain and itching"</a> and  <a class="medical medical_review" href="/z/d/html/16505.html" rel="external">"Paradigm-based treatment approaches for management of burn pain"</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Nutrition support</span><span class="headingEndMark"> — </span>Adequate nutritional support is imperative for the treatment of severely burned patients to reduce the catabolic effects [<a href="#rid86">86</a>]. An enteral route is preferred [<a href="#rid67">67</a>], but the timing of initiation may vary  (<a class="graphic graphic_algorithm graphicRef104119" href="/z/d/graphic/104119.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/821.html" rel="external">"Overview of nutrition support in burn patients"</a>.)</p><p>Various formulations and equations have been developed to address the increased energy requirements of adult and pediatric burn patients [<a href="#rid87">87-91</a>]. The most widely used formula is the Curreri formula, though this may overestimate nutritional needs [<a href="#rid91">91</a>]. (See  <a class="medical medical_review" href="/z/d/html/820.html" rel="external">"Nutritional demands and enteral formulas for adult surgical patients", section on 'Calculating energy requirements'</a>.)</p><p>Increased lipid administration to reduce fatty acid deficiency is commonplace in nutritional supplementation of nonburn critically ill patients but in burn patients may increase complications, including hyperlipidemia, hypoxemia, fatty liver infiltration, higher incidence of infection, and higher postoperative mortality [<a href="#rid50">50,79,92,93</a>]. The livers of burn patients secrete less very low-density lipoprotein (VLDL), and this contributes significantly to triglyceride accumulation in the liver [<a href="#rid94">94</a>]. Hence, the extent to which exogenous lipids can be used as an energy source after burn injury is considerably limited [<a href="#rid36">36,42,95</a>]. </p><p>Whether supplemental administration of <a class="drug drug_general" data-topicid="8747" href="/z/d/drug information/8747.html" rel="external">glutamine</a> provides a clinical benefit is not known for certain. In animal models, glutamine administration reduces the hypermetabolic response through a variety of mechanisms [<a href="#rid96">96-98</a>]. In a small multicenter trial, resting energy expenditure, serum catecholamines, glucagon, lactate, and homeostasis model assessment were significantly lower among 27 severely burned patients (TBSA 30 to 70 percent) who received intravenous glutamine compared with 28 patients who did not [<a href="#rid99">99</a>]. While intravenous glutamine at doses of 0.3 to 0.5 grams per kilogram per day attenuated the post-burn hypermetabolic response and reduced organ damage, the length of hospitalization and mortality rates were similar between the groups.</p><p class="headingAnchor" id="H22"><span class="h3">Glycemic control</span><span class="headingEndMark"> — </span>Nutritional management includes avoidance of hyperglycemia, which is associated with higher morbidity and mortality in moderate-to-severe burn patients. (See  <a class="medical medical_review" href="/z/d/html/1600.html" rel="external">"Glycemic control in critically ill adult and pediatric patients"</a>.)</p><p>The ideal target glucose range is uncertain. In general, target glucose levels for moderately to severely burned patients include:</p><p class="bulletIndent1"><span class="glyph">●</span>Morning glucose level of 130 mg/dL (7.2 mmol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>Daily average glucose level of 140 mg/dL (7.8 mmol/L) for at least 70 percent of the hospital admission </p><p></p><p>However, additional clinical trials are needed to define the ideal glucose levels for the treatment of critically ill, trauma, and severely burned adult patients. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Insulin</strong> – In severely burned patients, insulin administered during acute hospitalization improves muscle protein synthesis, accelerates donor-site healing time, attenuates LBM loss and the acute phase response, and reduces infection and mortality rates [<a href="#rid100">100-108</a>]. In addition to its anabolic actions, insulin exerts anti-inflammatory effects, potentially neutralizing the proinflammatory actions of glucose [<a href="#rid105">105</a>]. These results suggest a dual benefit of insulin administration: reduction of proinflammatory effects of glucose by restoration of euglycemia and a proposed additional insulin-mediated anti-inflammatory effect [<a href="#rid109">109</a>]. Maintaining a continuous insulin infusion in burn patients can be challenging since these patients require a large caloric load. In addition, burn patients require frequent operations and dressing changes, which intermittently halts enteral nutrition, leading to variations in glucose levels [<a href="#rid2">2</a>]. Insulin resistance can also develop during the acute phase and persist for three years in pediatric burn patients [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/1770.html" rel="external">"Management of diabetes mellitus in hospitalized patients", section on 'Patients receiving enteral or parenteral feedings'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">Metformin</a> – Metformin, a biguanide, counters the two main metabolic processes that underlie burn injury-induced hyperglycemia by inhibiting gluconeogenesis and augmenting peripheral insulin sensitivity [<a href="#rid110">110-114</a>]. A trial that randomly assigned 44 severely burned patients to metformin or insulin found that metformin controlled blood equally as well as insulin but with less hypoglycemia (15 versus 6 percent), and it also improved insulin sensitivity (as measured by oral glucose tolerance test at discharge) [<a href="#rid115">115</a>]. (See  <a class="medical medical_review" href="/z/d/html/1809.html" rel="external">"Metformin in the treatment of adults with type 2 diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incretin-based therapies</strong> – Another approach to treating hyperglycemia in burn patients without increasing the risk of hypoglycemia is incretin-based therapies. The incretins include glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1). Exogenous GLP-1 reduces glucose concentration in patients with type 2 diabetes after major surgery [<a href="#rid116">116</a>] and in those who are critically ill without diabetes and receiving enteral nutrition [<a href="#rid117">117</a>]. In a trial that included 24 severely burned patients, <a class="drug drug_general" data-topicid="9005" href="/z/d/drug information/9005.html" rel="external">exenatide</a>, a synthetic peptide that possesses incretin-mimetic actions including suppression of glucagon secretion and activation of GLP-1, significantly decreased the amount of exogenous insulin required to maintain glucose levels between 80 and 140 mg/dL (4.4 to 7.8 mmol/L) [<a href="#rid118">118</a>]. The GLP-1 analogue tested in this trial appears to be safe and reliably modulated glucose in these patients. (See  <a class="medical medical_review" href="/z/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus"</a>.)</p><p></p><p class="headingAnchor" id="H2509324397"><span class="h2">Exercise and adjunctive measures</span><span class="headingEndMark"> — </span>A balanced physical therapy program is essential to restore metabolic variables and prevent burn wound contractures. In a randomized trial of progressive resistance and aerobic exercises versus traditional outpatient home therapy in 21 children, both groups had a significant increase in muscle strength compared with baseline [<a href="#rid119">119</a>]. However, the study group had significantly greater improvements in muscle strength (80 versus 38 percent in the home group). The study group also improved the distance walked (40 versus 12 percent).</p><p class="headingAnchor" id="H3910553962"><span class="h2">Recombinant human growth hormone</span><span class="headingEndMark"> — </span>Delays in growth are frequently observed in children who suffer severe burns. It is hypothesized that the delay in vertical growth is related to a low serum level of growth hormone. In a two-year observational study in children with moderate-to-severe burns, there was a significant difference in height velocity in 38 children treated with rhGH compared with 41 children who did not receive rhGH (47<sup>th</sup> versus 32<sup>nd</sup> percentile) [<a href="#rid120">120</a>]. However, rhGH did not attenuate the hypermetabolic response.</p><p>Neither short- nor long-term administration of rhGH was associated with an increase in mortality in severely burned children [<a href="#rid121">121,122</a>]. However, rhGH is associated with an increase in mortality in adult burn patients and is not recommended in this population [<a href="#rid123">123</a>]. For children, rhGH use is recommended during the chronic phase of burn management, and rhGH should <strong>not</strong> be used concurrently with an infection or sepsis. Administration during the acute phase is associated with an increased risk of septic events [<a href="#rid65">65,120,123-126</a>]. </p><p>In a systematic review that included 13 randomized trials (six in children, seven in adults), treatment with rhGH shortened donor site healing time (by 3.15 days; 95% CI 1.54-4.75) and burn wound healing time (by 9.07 days; 95% CI 4.39-13.76) in adults compared with placebo [<a href="#rid127">127</a>]. In children, treatment with rhGH also shortened donor site healing time (by 1.70 days; 95% CI 0.87-2.53); data were not sufficient to assess burn wound healing time. Growth hormone increased the incidence of hyperglycemia in adults compared with placebo (risk ratio 2.43; 95% CI 1.54-3.85) but not in children. Treatment did not alter mortality or observed scarring. </p><p class="headingAnchor" id="H1398784948"><span class="h2">Environmental support</span><span class="headingEndMark"> — </span>Burn patients can lose as much as 4000 mL/m<sup>2</sup> burned/day of body water through evaporative loss from extensive burn wounds that have not healed or are not covered by grafts [<a href="#rid128">128</a>]. The altered physiologic state partly generates sufficient energy to offset heat losses associated with inevitable water loss. The body attempts to raise skin and core temperatures to 2ºC greater than normal. One prospective study found that raising the ambient temperature from 25ºC to 33ºC diminished the magnitude of this obligatory response from 2.0 to 1.4 times resting energy expenditure [<a href="#rid129">129</a>].</p><p class="headingAnchor" id="H3300330612"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117752.html" rel="external">"Society guideline links: Care of the patient with burn injury"</a>.)</p><p class="headingAnchor" id="H32"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The hypermetabolic response to injury is characterized by a hyperdynamic circulatory response, increased protein and lipid catabolism, and peripheral insulin resistance, which increase resting energy expenditure and body temperature and decrease total body protein, leading to muscle wasting. These responses occur in all trauma, surgical, or critically ill patients, but the magnitude to which they occur and duration are particularly severe and sustained for burn patients. (See <a class="local">'Hypermetabolic response'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Early excision and grafting of the burn wound is the most important intervention for treating patients with moderate-to-severe burn injuries, substantially reducing resting energy requirements. It also reduces the risk of burn wound infection and sepsis, length of hospital stay, and burn-related mortality. (See <a class="local">'Early excision and grafting'</a> above and  <a class="medical medical_review" href="/z/d/html/14985.html" rel="external">"Burn wound infection and sepsis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For children with moderate-to-severe burns, we suggest treatment with <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> for one year (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Propranolol attenuates the hypermetabolism and reverses muscle-protein catabolism. There is no evidence to support the routine use of propranolol in adult burn patients. (See <a class="local">'Propranolol'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Because burn injuries cause one of the most intense and prolonged types of pain, pain management is important to attenuate the hypermetabolic response. Intravenous opioids, continuous or bolused, are most often used to relieve pain. (See <a class="local">'Reduce pain and anxiety'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For stress-related hyperglycemia in burn patients without a past history of diabetes, we recommend treatment with insulin (intravenous or injectable) (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Insulin significantly lowers the incidence of sepsis and mortality in those patients with good glucose control compared with those who had poor control. (See <a class="local">'Glycemic control'</a> above and  <a class="medical medical_review" href="/z/d/html/821.html" rel="external">"Overview of nutrition support in burn patients", section on 'Glycemic control'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with moderate-to-severe burns, a balanced physical therapy program to restore metabolic variables, prevent burn wound contracture, improve body mass, and increase muscle strength should be included in the treatment plan. In addition, increasing the ambient temperature from 25 to 33ºC diminishes resting energy expenditure. (See <a class="local">'Exercise and adjunctive measures'</a> above and <a class="local">'Environmental support'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Herndon DN. Total Burn Care, 3rd edition, Saunders Elsevier, Philadelphia 2007.</li><li><a class="nounderline abstract_t">Herndon DN, Tompkins RG. Support of the metabolic response to burn injury. Lancet 2004; 363:1895.</a></li><li><a class="nounderline abstract_t">McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycemia. Crit Care Clin 2001; 17:107.</a></li><li><a class="nounderline abstract_t">Jeschke MG, Herndon DN. Burns in children: standard and new treatments. Lancet 2014; 383:1168.</a></li><li><a class="nounderline abstract_t">Atiyeh BS, Gunn SW, Dibo SA. Metabolic implications of severe burn injuries and their management: a systematic review of the literature. World J Surg 2008; 32:1857.</a></li><li><a class="nounderline abstract_t">Atiyeh BS, Gunn SW, Dibo SA. Nutritional and pharmacological modulation of the metabolic response of severely burned patients: review of the literature (part 1). Ann Burns Fire Disasters 2008; 21:63.</a></li><li><a class="nounderline abstract_t">Hart DW, Wolf SE, Mlcak R, et al. Persistence of muscle catabolism after severe burn. Surgery 2000; 128:312.</a></li><li><a class="nounderline abstract_t">American Burn Association/American College of Surgeons. Guidelines for the operation of burn centers. J Burn Care Res 2007; 28:134.</a></li><li><a class="nounderline abstract_t">Porter C, Tompkins RG, Finnerty CC, et al. The metabolic stress response to burn trauma: current understanding and therapies. Lancet 2016; 388:1417.</a></li><li><a class="nounderline abstract_t">Jeschke MG, Chinkes DL, Finnerty CC, et al. Pathophysiologic response to severe burn injury. Ann Surg 2008; 248:387.</a></li><li><a class="nounderline abstract_t">Stanojcic M, Abdullahi A, Rehou S, et al. Pathophysiological Response to Burn Injury in Adults. Ann Surg 2018; 267:576.</a></li><li><a class="nounderline abstract_t">Mlcak RP, Jeschke MG, Barrow RE, Herndon DN. The influence of age and gender on resting energy expenditure in severely burned children. Ann Surg 2006; 244:121.</a></li><li><a class="nounderline abstract_t">Przkora R, Barrow RE, Jeschke MG, et al. Body composition changes with time in pediatric burn patients. J Trauma 2006; 60:968.</a></li><li><a class="nounderline abstract_t">Dolecek R. Endocrine changes after burn trauma--a review. Keio J Med 1989; 38:262.</a></li><li><a class="nounderline abstract_t">Jeffries MK, Vance ML. Growth hormone and cortisol secretion in patients with burn injury. J Burn Care Rehabil 1992; 13:391.</a></li><li><a class="nounderline abstract_t">Klein GL, Bi LX, Sherrard DJ, et al. Evidence supporting a role of glucocorticoids in short-term bone loss in burned children. Osteoporos Int 2004; 15:468.</a></li><li><a class="nounderline abstract_t">GOODALL M, STONE C, HAYNES BW Jr. Urinary output of adrenaline and noradrenaline in severe thermal burns. Ann Surg 1957; 145:479.</a></li><li><a class="nounderline abstract_t">Coombes EJ, Batstone GF. Urine cortisol levels after burn injury. Burns Incl Therm Inj 1982; 8:333.</a></li><li class="breakAll">Norbury WB, Herndon DN. Modulation of the hypermetabolic response after burn injury. In: Total Burn Care, 3rd edition, Herndon DN (Ed), Saunders Elsevier, New York 2007. p.420.</li><li><a class="nounderline abstract_t">Sheridan RL. A great constitutional disturbance. N Engl J Med 2001; 345:1271.</a></li><li><a class="nounderline abstract_t">Pereira C, Murphy K, Jeschke M, Herndon DN. Post burn muscle wasting and the effects of treatments. Int J Biochem Cell Biol 2005; 37:1948.</a></li><li><a class="nounderline abstract_t">Rani M, Nicholson SE, Zhang Q, Schwacha MG. Damage-associated molecular patterns (DAMPs) released after burn are associated with inflammation and monocyte activation. Burns 2017; 43:297.</a></li><li><a class="nounderline abstract_t">Oppeltz RF, Rani M, Zhang Q, Schwacha MG. Burn-induced alterations in toll-like receptor-mediated responses by bronchoalveolar lavage cells. Cytokine 2011; 55:396.</a></li><li><a class="nounderline abstract_t">Maile R, Jones S, Pan Y, et al. Association between early airway damage-associated molecular patterns and subsequent bacterial infection in patients with inhalational and burn injury. Am J Physiol Lung Cell Mol Physiol 2015; 308:L855.</a></li><li><a class="nounderline abstract_t">Wolfe RR. Review: acute versus chronic response to burn injury. Circ Shock 1981; 8:105.</a></li><li><a class="nounderline abstract_t">Cuthbertson DP, Angeles Valero Zanuy MA, León Sanz ML. Post-shock metabolic response. 1942. Nutr Hosp 2001; 16:176.</a></li><li><a class="nounderline abstract_t">Galster AD, Bier DM, Cryer PE, Monafo WW. Plasma palmitate turnover in subjects with thermal injury. J Trauma 1984; 24:938.</a></li><li><a class="nounderline abstract_t">Cree MG, Aarsland A, Herndon DN, Wolfe RR. Role of fat metabolism in burn trauma-induced skeletal muscle insulin resistance. Crit Care Med 2007; 35:S476.</a></li><li><a class="nounderline abstract_t">Childs C, Heath DF, Little RA, Brotherston M. Glucose metabolism in children during the first day after burn injury. Arch Emerg Med 1990; 7:135.</a></li><li><a class="nounderline abstract_t">Pereira CT, Herndon DN. The pharmacologic modulation of the hypermetabolic response to burns. Adv Surg 2005; 39:245.</a></li><li><a class="nounderline abstract_t">Jeschke MG, Barrow RE, Herndon DN. Extended hypermetabolic response of the liver in severely burned pediatric patients. Arch Surg 2004; 139:641.</a></li><li><a class="nounderline abstract_t">Jeschke MG, Mlcak RP, Finnerty CC, et al. Burn size determines the inflammatory and hypermetabolic response. Crit Care 2007; 11:R90.</a></li><li><a class="nounderline abstract_t">Gauglitz GG, Herndon DN, Kulp GA, et al. Abnormal insulin sensitivity persists up to three years in pediatric patients post-burn. J Clin Endocrinol Metab 2009; 94:1656.</a></li><li><a class="nounderline abstract_t">Deitch EA. Nutritional support of the burn patient. Crit Care Clin 1995; 11:735.</a></li><li><a class="nounderline abstract_t">Dickerson RN, Gervasio JM, Riley ML, et al. Accuracy of predictive methods to estimate resting energy expenditure of thermally-injured patients. JPEN J Parenter Enteral Nutr 2002; 26:17.</a></li><li><a class="nounderline abstract_t">Demling RH, Seigne P. Metabolic management of patients with severe burns. World J Surg 2000; 24:673.</a></li><li><a class="nounderline abstract_t">Williams FN, Herndon DN, Suman OE, et al. Changes in cardiac physiology after severe burn injury. J Burn Care Res 2011; 32:269.</a></li><li><a class="nounderline abstract_t">Williams FN, Herndon DN, Kulp GA, Jeschke MG. Propranolol decreases cardiac work in a dose-dependent manner in severely burned children. Surgery 2011; 149:231.</a></li><li><a class="nounderline abstract_t">Jeschke MG, Gauglitz GG, Kulp GA, et al. Long-term persistance of the pathophysiologic response to severe burn injury. PLoS One 2011; 6:e21245.</a></li><li><a class="nounderline abstract_t">Gearhart MM, Parbhoo SK. Hyperglycemia in the critically ill patient. AACN Clin Issues 2006; 17:50.</a></li><li><a class="nounderline abstract_t">Robinson LE, van Soeren MH. Insulin resistance and hyperglycemia in critical illness: role of insulin in glycemic control. AACN Clin Issues 2004; 15:45.</a></li><li><a class="nounderline abstract_t">Wolfe RR, Herndon DN, Jahoor F, et al. Effect of severe burn injury on substrate cycling by glucose and fatty acids. N Engl J Med 1987; 317:403.</a></li><li><a class="nounderline abstract_t">Carlson GL. Insulin resistance and glucose-induced thermogenesis in critical illness. Proc Nutr Soc 2001; 60:381.</a></li><li><a class="nounderline abstract_t">Wolfe RR, Durkot MJ, Allsop JR, Burke JF. Glucose metabolism in severely burned patients. Metabolism 1979; 28:1031.</a></li><li><a class="nounderline abstract_t">Cree MG, Zwetsloot JJ, Herndon DN, et al. Insulin sensitivity and mitochondrial function are improved in children with burn injury during a randomized controlled trial of fenofibrate. Ann Surg 2007; 245:214.</a></li><li><a class="nounderline abstract_t">Hunt DG, Ivy JL. Epinephrine inhibits insulin-stimulated muscle glucose transport. J Appl Physiol (1985) 2002; 93:1638.</a></li><li><a class="nounderline abstract_t">Xu H, Yu YM, Ma H, et al. Glucose metabolism during the early "flow phase" after burn injury. J Surg Res 2013; 179:e83.</a></li><li><a class="nounderline abstract_t">Baracos V, Rodemann HP, Dinarello CA, Goldberg AL. Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). A mechanism for the increased degradation of muscle proteins during fever. N Engl J Med 1983; 308:553.</a></li><li><a class="nounderline abstract_t">Jahoor F, Desai M, Herndon DN, Wolfe RR. Dynamics of the protein metabolic response to burn injury. Metabolism 1988; 37:330.</a></li><li class="breakAll">Saffle JR, Graves C. Nutritional support of the burned patient. In: Total Burn Care, 3rd edition, Herndon DN (Ed), Saunders Elsevier, New York 2007. p.398.</li><li><a class="nounderline abstract_t">Porter C, Herndon DN, Sidossis LS, Børsheim E. The impact of severe burns on skeletal muscle mitochondrial function. Burns 2013; 39:1039.</a></li><li><a class="nounderline abstract_t">DeFronzo RA, Jacot E, Jequier E, et al. The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes 1981; 30:1000.</a></li><li><a class="nounderline abstract_t">Petruzzelli M, Schweiger M, Schreiber R, et al. A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab 2014; 20:433.</a></li><li><a class="nounderline abstract_t">Patsouris D, Qi P, Abdullahi A, et al. Burn Induces Browning of the Subcutaneous White Adipose Tissue in Mice and Humans. Cell Rep 2015; 13:1538.</a></li><li><a class="nounderline abstract_t">Sidossis LS, Porter C, Saraf MK, et al. Browning of Subcutaneous White Adipose Tissue in Humans after Severe Adrenergic Stress. Cell Metab 2015; 22:219.</a></li><li><a class="nounderline abstract_t">McClave SA, Snider HL. Use of indirect calorimetry in clinical nutrition. Nutr Clin Pract 1992; 7:207.</a></li><li><a class="nounderline abstract_t">Arora NS, Rochester DF. Respiratory muscle strength and maximal voluntary ventilation in undernourished patients. Am Rev Respir Dis 1982; 126:5.</a></li><li><a class="nounderline abstract_t">Rutan RL, Herndon DN. Growth delay in postburn pediatric patients. Arch Surg 1990; 125:392.</a></li><li><a class="nounderline abstract_t">Deng H, Chen J, Li F, et al. Effects of mobility training on severe burn patients in the BICU: A retrospective cohort study. Burns 2016; 42:1404.</a></li><li><a class="nounderline abstract_t">Clark DE, Lowman JD, Griffin RL, et al. Effectiveness of an early mobilization protocol in a trauma and burns intensive care unit: a retrospective cohort study. Phys Ther 2013; 93:186.</a></li><li><a class="nounderline abstract_t">Li H, Guo Y, Yang Z, et al. The efficacy and safety of oxandrolone treatment for patients with severe burns: A systematic review and meta-analysis. Burns 2016; 42:717.</a></li><li class="breakAll">Gemini Laboratories, LLC, et al.; Withdrawal of Approval of One New Drug Application for OXANDRIN (Oxandrolone) Tablets and Four Abbreviated New Drug Applications for Oxandrolone Tablets. https://www.federalregister.gov/documents/2023/06/28/2023-13733/gemini-laboratories-llc-et-al-withdrawal-of-approval-of-one-new-drug-application-for-oxandrin. (Accessed on June 30, 2023).</li><li><a class="nounderline abstract_t">Ong YS, Samuel M, Song C. Meta-analysis of early excision of burns. Burns 2006; 32:145.</a></li><li><a class="nounderline abstract_t">Janzekovic Z. A new concept in the early excision and immediate grafting of burns. J Trauma 1970; 10:1103.</a></li><li><a class="nounderline abstract_t">Wu X, Herndon DN, Wolf SE. Growth hormone down-regulation of Interleukin-1beta and Interleukin-6 induced acute phase protein gene expression is associated with increased gene expression of suppressor of cytokine signal-3. Shock 2003; 19:314.</a></li><li><a class="nounderline abstract_t">Munster AM, Smith-Meek M, Sharkey P. The effect of early surgical intervention on mortality and cost-effectiveness in burn care, 1978-91. Burns 1994; 20:61.</a></li><li><a class="nounderline abstract_t">Hart DW, Wolf SE, Chinkes DL, et al. Effects of early excision and aggressive enteral feeding on hypermetabolism, catabolism, and sepsis after severe burn. J Trauma 2003; 54:755.</a></li><li><a class="nounderline abstract_t">Williams FN, Herndon DN, Jeschke MG. The hypermetabolic response to burn injury and interventions to modify this response. Clin Plast Surg 2009; 36:583.</a></li><li><a class="nounderline abstract_t">Prasanna M, Mishra P, Thomas C. Delayed primary closure of the burn wounds. Burns 2004; 30:169.</a></li><li><a class="nounderline abstract_t">Atiyeh BS, Dham R, Kadry M, et al. Benefit-cost analysis of moist exposed burn ointment. Burns 2002; 28:659.</a></li><li><a class="nounderline abstract_t">Ramzy PI, Barret JP, Herndon DN. Thermal injury. Crit Care Clin 1999; 15:333.</a></li><li><a class="nounderline abstract_t">Gus EI, Shahrokhi S, Jeschke MG. Anabolic and anticatabolic agents used in burn care: What is known and what is yet to be learned. Burns 2020; 46:19.</a></li><li><a class="nounderline abstract_t">Flores O, Stockton K, Roberts JA, et al. The efficacy and safety of adrenergic blockade after burn injury: A systematic review and meta-analysis. J Trauma Acute Care Surg 2016; 80:146.</a></li><li><a class="nounderline abstract_t">Herndon DN, Hart DW, Wolf SE, et al. Reversal of catabolism by beta-blockade after severe burns. N Engl J Med 2001; 345:1223.</a></li><li><a class="nounderline abstract_t">Arbabi S, Ahrns KS, Wahl WL, et al. Beta-blocker use is associated with improved outcomes in adult burn patients. J Trauma 2004; 56:265.</a></li><li><a class="nounderline abstract_t">Baron PW, Barrow RE, Pierre EJ, Herndon DN. Prolonged use of propranolol safely decreases cardiac work in burned children. J Burn Care Rehabil 1997; 18:223.</a></li><li><a class="nounderline abstract_t">Gore DC, Honeycutt D, Jahoor F, et al. Propranolol diminishes extremity blood flow in burned patients. Ann Surg 1991; 213:568.</a></li><li><a class="nounderline abstract_t">Pereira CT, Jeschke MG, Herndon DN. Beta-blockade in burns. Novartis Found Symp 2007; 280:238.</a></li><li><a class="nounderline abstract_t">Barret JP, Jeschke MG, Herndon DN. Fatty infiltration of the liver in severely burned pediatric patients: autopsy findings and clinical implications. J Trauma 2001; 51:736.</a></li><li><a class="nounderline abstract_t">Aarsland A, Chinkes D, Wolfe RR, et al. Beta-blockade lowers peripheral lipolysis in burn patients receiving growth hormone. Rate of hepatic very low density lipoprotein triglyceride secretion remains unchanged. Ann Surg 1996; 223:777.</a></li><li><a class="nounderline abstract_t">Herndon DN, Rodriguez NA, Diaz EC, et al. Long-term propranolol use in severely burned pediatric patients: a randomized controlled study. Ann Surg 2012; 256:402.</a></li><li><a class="nounderline abstract_t">Jeschke MG, Norbury WB, Finnerty CC, et al. Propranolol does not increase inflammation, sepsis, or infectious episodes in severely burned children. J Trauma 2007; 62:676.</a></li><li><a class="nounderline abstract_t">Cheema SA, Ahmed UT, Nasir H, et al. Effects of Propranolol in Accelerating Wound Healing and Attenuation of Hypermetabolism in Adult Burn Patients. J Coll Physicians Surg Pak 2020; 30:46.</a></li><li><a class="nounderline abstract_t">Murphy KD, Lee JO, Herndon DN. Current pharmacotherapy for the treatment of severe burns. Expert Opin Pharmacother 2003; 4:369.</a></li><li><a class="nounderline abstract_t">Hedderich R, Ness TJ. Analgesia for trauma and burns. Crit Care Clin 1999; 15:167.</a></li><li><a class="nounderline abstract_t">Newsome TW, Mason AD Jr, Pruitt BA Jr. Weight loss following thermal injury. Ann Surg 1973; 178:215.</a></li><li><a class="nounderline abstract_t">Curreri PW, Richmond D, Marvin J, Baxter CR. Dietary requirements of patients with major burns. J Am Diet Assoc 1974; 65:415.</a></li><li><a class="nounderline abstract_t">Allard JP, Pichard C, Hoshino E, et al. Validation of a new formula for calculating the energy requirements of burn patients. JPEN J Parenter Enteral Nutr 1990; 14:115.</a></li><li><a class="nounderline abstract_t">Hildreth MA, Herndon DN, Desai MH, Broemeling LD. Current treatment reduces calories required to maintain weight in pediatric patients with burns. J Burn Care Rehabil 1990; 11:405.</a></li><li><a class="nounderline abstract_t">Herndon DN, Curreri PW. Metabolic response to thermal injury and its nutritional support. Cutis 1978; 22:501.</a></li><li><a class="nounderline abstract_t">Lam NN, Tien NG, Khoa CM. Early enteral feeding for burned patients--an effective method which should be encouraged in developing countries. Burns 2008; 34:192.</a></li><li><a class="nounderline abstract_t">Garrel DR, Razi M, Larivière F, et al. Improved clinical status and length of care with low-fat nutrition support in burn patients. JPEN J Parenter Enteral Nutr 1995; 19:482.</a></li><li><a class="nounderline abstract_t">Mochizuki H, Trocki O, Dominioni L, et al. Optimal lipid content for enteral diets following thermal injury. JPEN J Parenter Enteral Nutr 1984; 8:638.</a></li><li><a class="nounderline abstract_t">Aarsland A, Chinkes D, Wolfe RR. Contributions of de novo synthesis of fatty acids to total VLDL-triglyceride secretion during prolonged hyperglycemia/hyperinsulinemia in normal man. J Clin Invest 1996; 98:2008.</a></li><li><a class="nounderline abstract_t">Herndon DN, Nguyen TT, Wolfe RR, et al. Lipolysis in burned patients is stimulated by the beta 2-receptor for catecholamines. Arch Surg 1994; 129:1301.</a></li><li><a class="nounderline abstract_t">Yang G, Zhang Y, Wu D, et al. 1H-NMR metabolomics identifies significant changes in hypermetabolism after glutamine administration in burned rats. Am J Transl Res 2019; 11:7286.</a></li><li><a class="nounderline abstract_t">Fan J, Wu J, Wu LD, et al. Effect of parenteral glutamine supplementation combined with enteral nutrition on Hsp90 expression and lymphoid organ apoptosis in severely burned rats. Burns 2016; 42:1494.</a></li><li><a class="nounderline abstract_t">Yang YJ, Liu MM, Zhang Y, et al. Effectiveness and mechanism study of glutamine on alleviating hypermetabolism in burned rats. Nutrition 2020; 79-80:110934.</a></li><li><a class="nounderline abstract_t">Wang ZE, Zheng JJ, Bin Feng J, et al. Glutamine relieves the hypermetabolic response and reduces organ damage in severe burn patients: A multicenter, randomized controlled clinical trial. Burns 2022; 48:1606.</a></li><li><a class="nounderline abstract_t">Ferrando AA, Chinkes DL, Wolf SE, et al. A submaximal dose of insulin promotes net skeletal muscle protein synthesis in patients with severe burns. Ann Surg 1999; 229:11.</a></li><li><a class="nounderline abstract_t">Pierre EJ, Barrow RE, Hawkins HK, et al. Effects of insulin on wound healing. J Trauma 1998; 44:342.</a></li><li><a class="nounderline abstract_t">Thomas SJ, Morimoto K, Herndon DN, et al. The effect of prolonged euglycemic hyperinsulinemia on lean body mass after severe burn. Surgery 2002; 132:341.</a></li><li><a class="nounderline abstract_t">Zhang XJ, Chinkes DL, Wolf SE, Wolfe RR. Insulin but not growth hormone stimulates protein anabolism in skin wound and muscle. Am J Physiol 1999; 276:E712.</a></li><li><a class="nounderline abstract_t">Jeschke MG, Klein D, Bolder U, Einspanier R. Insulin attenuates the systemic inflammatory response in endotoxemic rats. Endocrinology 2004; 145:4084.</a></li><li><a class="nounderline abstract_t">Jeschke MG, Klein D, Herndon DN. Insulin treatment improves the systemic inflammatory reaction to severe trauma. Ann Surg 2004; 239:553.</a></li><li><a class="nounderline abstract_t">Jeschke MG, Rensing H, Klein D, et al. Insulin prevents liver damage and preserves liver function in lipopolysaccharide-induced endotoxemic rats. J Hepatol 2005; 42:870.</a></li><li><a class="nounderline abstract_t">Klein D, Schubert T, Horch RE, et al. Insulin treatment improves hepatic morphology and function through modulation of hepatic signals after severe trauma. Ann Surg 2004; 240:340.</a></li><li><a class="nounderline abstract_t">Jeschke MG, Kulp GA, Kraft R, et al. Intensive insulin therapy in severely burned pediatric patients: a prospective randomized trial. Am J Respir Crit Care Med 2010; 182:351.</a></li><li><a class="nounderline abstract_t">Dandona P, Chaudhuri A, Mohanty P, Ghanim H. Anti-inflammatory effects of insulin. Curr Opin Clin Nutr Metab Care 2007; 10:511.</a></li><li><a class="nounderline abstract_t">Gore DC, Wolf SE, Herndon DN, Wolfe RR. Metformin blunts stress-induced hyperglycemia after thermal injury. J Trauma 2003; 54:555.</a></li><li><a class="nounderline abstract_t">DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995; 333:541.</a></li><li><a class="nounderline abstract_t">Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333:550.</a></li><li><a class="nounderline abstract_t">Gore DC, Herndon DN, Wolfe RR. Comparison of peripheral metabolic effects of insulin and metformin following severe burn injury. J Trauma 2005; 59:316.</a></li><li><a class="nounderline abstract_t">Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334:574.</a></li><li><a class="nounderline abstract_t">Jeschke MG, Abdullahi A, Burnett M, et al. Glucose Control in Severely Burned Patients Using Metformin: An Interim Safety and Efficacy Analysis of a Phase II Randomized Controlled Trial. Ann Surg 2016; 264:518.</a></li><li><a class="nounderline abstract_t">Meier JJ, Weyhe D, Michaely M, et al. Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. Crit Care Med 2004; 32:848.</a></li><li><a class="nounderline abstract_t">Deane AM, Chapman MJ, Fraser RJ, et al. The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study. Crit Care 2009; 13:R67.</a></li><li><a class="nounderline abstract_t">Mecott GA, Herndon DN, Kulp GA, et al. The use of exenatide in severely burned pediatric patients. Crit Care 2010; 14:R153.</a></li><li><a class="nounderline abstract_t">Cucuzzo NA, Ferrando A, Herndon DN. The effects of exercise programming vs traditional outpatient therapy in the rehabilitation of severely burned children. J Burn Care Rehabil 2001; 22:214.</a></li><li><a class="nounderline abstract_t">Aili Low JF, Barrow RE, Mittendorfer B, et al. The effect of short-term growth hormone treatment on growth and energy expenditure in burned children. Burns 2001; 27:447.</a></li><li><a class="nounderline abstract_t">Branski LK, Herndon DN, Barrow RE, et al. Randomized controlled trial to determine the efficacy of long-term growth hormone treatment in severely burned children. Ann Surg 2009; 250:514.</a></li><li><a class="nounderline abstract_t">Ramirez RJ, Wolf SE, Barrow RE, Herndon DN. Growth hormone treatment in pediatric burns: a safe therapeutic approach. Ann Surg 1998; 228:439.</a></li><li><a class="nounderline abstract_t">Jeschke MG, Herndon DN, Wolf SE, et al. Recombinant human growth hormone alters acute phase reactant proteins, cytokine expression, and liver morphology in burned rats. J Surg Res 1999; 83:122.</a></li><li><a class="nounderline abstract_t">Jeschke MG, Chrysopoulo MT, Herndon DN, Wolf SE. Increased expression of insulin-like growth factor-I in serum and liver after recombinant human growth hormone administration in thermally injured rats. J Surg Res 1999; 85:171.</a></li><li><a class="nounderline abstract_t">Hart DW, Herndon DN, Klein G, et al. Attenuation of posttraumatic muscle catabolism and osteopenia by long-term growth hormone therapy. Ann Surg 2001; 233:827.</a></li><li><a class="nounderline abstract_t">Herndon DN, Barrow RE, Kunkel KR, et al. Effects of recombinant human growth hormone on donor-site healing in severely burned children. Ann Surg 1990; 212:424.</a></li><li><a class="nounderline abstract_t">Breederveld RS, Tuinebreijer WE. Recombinant human growth hormone for treating burns and donor sites. Cochrane Database Syst Rev 2014; :CD008990.</a></li><li><a class="nounderline abstract_t">Zawacki BE, Spitzer KW, Mason AD Jr, Johns LA. Does increased evaporative water loss cause hypermetabolism in burned patients? Ann Surg 1970; 171:236.</a></li><li><a class="nounderline abstract_t">Wilmore DW, Mason AD Jr, Johnson DW, Pruitt BA Jr. Effect of ambient temperature on heat production and heat loss in burn patients. J Appl Physiol 1975; 38:593.</a></li></ol></div><div id="topicVersionRevision">Topic 818 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Herndon DN. Total Burn Care, 3rd edition, Saunders Elsevier, Philadelphia 2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15183630" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Support of the metabolic response to burn injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11219223" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Stress-induced hyperglycemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24034453" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Burns in children: standard and new treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18454355" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Metabolic implications of severe burn injuries and their management: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21991114" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Nutritional and pharmacological modulation of the metabolic response of severely burned patients: review of the literature (part 1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10923010" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Persistence of muscle catabolism after severe burn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17211214" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Guidelines for the operation of burn centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27707498" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The metabolic stress response to burn trauma: current understanding and therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18791359" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pathophysiologic response to severe burn injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29408836" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pathophysiological Response to Burn Injury in Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16794397" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The influence of age and gender on resting energy expenditure in severely burned children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16688056" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Body composition changes with time in pediatric burn patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2511373" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Endocrine changes after burn trauma--a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1429807" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Growth hormone and cortisol secretion in patients with burn injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15205718" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Evidence supporting a role of glucocorticoids in short-term bone loss in burned children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13412024" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Urinary output of adrenaline and noradrenaline in severe thermal burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7093798" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Urine cortisol levels after burn injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7093798" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Urine cortisol levels after burn injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11680449" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A great constitutional disturbance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16109499" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Post burn muscle wasting and the effects of treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28341255" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Damage-associated molecular patterns (DAMPs) released after burn are associated with inflammation and monocyte activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21696980" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Burn-induced alterations in toll-like receptor-mediated responses by bronchoalveolar lavage cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25770180" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Association between early airway damage-associated molecular patterns and subsequent bacterial infection in patients with inhalational and burn injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7016359" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Review: acute versus chronic response to burn injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11708288" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Post-shock metabolic response. 1942.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6389897" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Plasma palmitate turnover in subjects with thermal injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17713396" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Role of fat metabolism in burn trauma-induced skeletal muscle insulin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2152453" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Glucose metabolism in children during the first day after burn injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16250555" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The pharmacologic modulation of the hypermetabolic response to burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15197091" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Extended hypermetabolic response of the liver in severely burned pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17716366" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Burn size determines the inflammatory and hypermetabolic response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19240154" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Abnormal insulin sensitivity persists up to three years in pediatric patients post-burn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7552980" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Nutritional support of the burn patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11833748" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Accuracy of predictive methods to estimate resting energy expenditure of thermally-injured patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10773119" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Metabolic management of patients with severe burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21228708" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Changes in cardiac physiology after severe burn injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20598332" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Propranolol decreases cardiac work in a dose-dependent manner in severely burned children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21789167" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Long-term persistance of the pathophysiologic response to severe burn injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16462409" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Hyperglycemia in the critically ill patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14767364" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Insulin resistance and hyperglycemia in critical illness: role of insulin in glycemic control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3614284" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Effect of severe burn injury on substrate cycling by glucose and fatty acids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11681813" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Insulin resistance and glucose-induced thermogenesis in critical illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/491960" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Glucose metabolism in severely burned patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17245174" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Insulin sensitivity and mitochondrial function are improved in children with burn injury during a randomized controlled trial of fenofibrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12381748" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Epinephrine inhibits insulin-stimulated muscle glucose transport.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22459295" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Glucose metabolism during the early "flow phase" after burn injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6402699" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). A mechanism for the increased degradation of muscle proteins during fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3282147" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Dynamics of the protein metabolic response to burn injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3282147" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Dynamics of the protein metabolic response to burn injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23664225" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The impact of severe burns on skeletal muscle mitochondrial function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7030826" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25043816" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A switch from white to brown fat increases energy expenditure in cancer-associated cachexia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26586436" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Burn Induces Browning of the Subcutaneous White Adipose Tissue in Mice and Humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26244931" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Browning of Subcutaneous White Adipose Tissue in Humans after Severe Adrenergic Stress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1289691" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Use of indirect calorimetry in clinical nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7091909" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Respiratory muscle strength and maximal voluntary ventilation in undernourished patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2306187" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Growth delay in postburn pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27595451" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Effects of mobility training on severe burn patients in the BICU: A retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22879442" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Effectiveness of an early mobilization protocol in a trauma and burns intensive care unit: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26454425" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The efficacy and safety of oxandrolone treatment for patients with severe burns: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26454425" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The efficacy and safety of oxandrolone treatment for patients with severe burns: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16414197" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Meta-analysis of early excision of burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4921723" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A new concept in the early excision and immediate grafting of burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12688541" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Growth hormone down-regulation of Interleukin-1beta and Interleukin-6 induced acute phase protein gene expression is associated with increased gene expression of suppressor of cytokine signal-3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8148080" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The effect of early surgical intervention on mortality and cost-effectiveness in burn care, 1978-91.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12707540" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Effects of early excision and aggressive enteral feeding on hypermetabolism, catabolism, and sepsis after severe burn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19793553" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The hypermetabolic response to burn injury and interventions to modify this response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15019128" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Delayed primary closure of the burn wounds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12417161" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Benefit-cost analysis of moist exposed burn ointment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10331132" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Thermal injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31852612" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Anabolic and anticatabolic agents used in burn care: What is known and what is yet to be learned.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26517779" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The efficacy and safety of adrenergic blockade after burn injury: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11680441" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Reversal of catabolism by beta-blockade after severe burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14960966" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Beta-blocker use is associated with improved outcomes in adult burn patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9169945" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Prolonged use of propranolol safely decreases cardiac work in burned children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2039287" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Propranolol diminishes extremity blood flow in burned patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17380798" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Beta-blockade in burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11586168" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Fatty infiltration of the liver in severely burned pediatric patients: autopsy findings and clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8645051" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Beta-blockade lowers peripheral lipolysis in burn patients receiving growth hormone. Rate of hepatic very low density lipoprotein triglyceride secretion remains unchanged.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22895351" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Long-term propranolol use in severely burned pediatric patients: a randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17414346" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Propranolol does not increase inflammation, sepsis, or infectious episodes in severely burned children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31931932" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Effects of Propranolol in Accelerating Wound Healing and Attenuation of Hypermetabolism in Adult Burn Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12614189" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Current pharmacotherapy for the treatment of severe burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9929793" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Analgesia for trauma and burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4198796" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Weight loss following thermal injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4213656" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Dietary requirements of patients with major burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2112617" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Validation of a new formula for calculating the energy requirements of burn patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2123202" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Current treatment reduces calories required to maintain weight in pediatric patients with burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/699632" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Metabolic response to thermal injury and its nutritional support.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17804169" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Early enteral feeding for burned patients--an effective method which should be encouraged in developing countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8748363" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Improved clinical status and length of care with low-fat nutrition support in burn patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6441004" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Optimal lipid content for enteral diets following thermal injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8903319" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Contributions of de novo synthesis of fatty acids to total VLDL-triglyceride secretion during prolonged hyperglycemia/hyperinsulinemia in normal man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7986160" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Lipolysis in burned patients is stimulated by the beta 2-receptor for catecholamines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31934278" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : 1H-NMR metabolomics identifies significant changes in hypermetabolism after glutamine administration in burned rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27613477" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Effect of parenteral glutamine supplementation combined with enteral nutrition on Hsp90 expression and lymphoid organ apoptosis in severely burned rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32847775" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Effectiveness and mechanism study of glutamine on alleviating hypermetabolism in burned rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34973853" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Glutamine relieves the hypermetabolic response and reduces organ damage in severe burn patients: A multicenter, randomized controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9923795" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : A submaximal dose of insulin promotes net skeletal muscle protein synthesis in patients with severe burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9498508" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Effects of insulin on wound healing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12219032" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : The effect of prolonged euglycemic hyperinsulinemia on lean body mass after severe burn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10198308" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Insulin but not growth hormone stimulates protein anabolism in skin wound and muscle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15192048" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Insulin attenuates the systemic inflammatory response in endotoxemic rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15024317" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Insulin treatment improves the systemic inflammatory reaction to severe trauma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15885358" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Insulin prevents liver damage and preserves liver function in lipopolysaccharide-induced endotoxemic rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15273560" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Insulin treatment improves hepatic morphology and function through modulation of hepatic signals after severe trauma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20395554" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Intensive insulin therapy in severely burned pediatric patients: a prospective randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17563472" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Anti-inflammatory effects of insulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12634538" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Metformin blunts stress-induced hyperglycemia after thermal injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7623902" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7623903" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16294070" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Comparison of peripheral metabolic effects of insulin and metformin following severe burn injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8569826" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Metformin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27355267" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Glucose Control in Severely Burned Patients Using Metformin: An Interim Safety and Efficacy Analysis of a Phase II Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15090972" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19439067" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20701787" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : The use of exenatide in severely burned pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11403243" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : The effects of exercise programming vs traditional outpatient therapy in the rehabilitation of severely burned children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11451596" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : The effect of short-term growth hormone treatment on growth and energy expenditure in burned children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19734776" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Randomized controlled trial to determine the efficacy of long-term growth hormone treatment in severely burned children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9790334" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Growth hormone treatment in pediatric burns: a safe therapeutic approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10329105" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Recombinant human growth hormone alters acute phase reactant proteins, cytokine expression, and liver morphology in burned rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10383855" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Increased expression of insulin-like growth factor-I in serum and liver after recombinant human growth hormone administration in thermally injured rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11371741" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Attenuation of posttraumatic muscle catabolism and osteopenia by long-term growth hormone therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2121109" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Effects of recombinant human growth hormone on donor-site healing in severely burned children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25222766" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Recombinant human growth hormone for treating burns and donor sites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5413459" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Does increased evaporative water loss cause hypermetabolism in burned patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1141088" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Effect of ambient temperature on heat production and heat loss in burn patients.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
